US IPO Pipeline SEC S-1 Filings — June 09, 2026

09-06-2026

Coeptis Therapeutics Holdings, Inc. filed an S-1 registration statement on June 9, 2026, registering up to 41,584,562 shares of common stock for resale by selling securityholders following a business combination with Z Squared Inc. The company will not receive any proceeds from the resale. The filing reveals substantial doubt about the company's ability to continue as a going concern, with an accumulated deficit of approximately $113.9 million as of March 31, 2026, and a net loss of $4.0 million for the three months ended March 31, 2026. Additionally, the company's mining operations are unprofitable at current Dogecoin prices ($0.085/DOGE) versus a breakeven of $0.13/DOGE, and it faces significant risks including reliance on a single hosting provider (Minting Dome) and highly volatile cryptocurrency markets.

• · The lock-up and leak-out restrictions on the shares distributed by BSG generally prohibit sales unless the volume-weighted average price over 10 trading days exceeds $16.00 per share, limit monthly sales to 1/18th of shares received, cap monthly sales at 5% of average daily trading volume, and prohibit short sales; restrictions expire on October 27, 2027 or earlier if the closing price exceeds $35.00 for two consecutive trading days.
• · The company's mining revenues are denominated in DOGE and LTC, which it intends to convert to fiat or stablecoins promptly.
• · The company is entirely dependent on the Minting Dome Master Services Agreement for hosting, power, and operational infrastructure.
• · The board of directors consists of four members: David Halabu, Adam Sohn, Bryan Fuerst, and Kenneth Cooper.
• · The company's common stock is listed on the Nasdaq Global Market under the symbol 'ZSQR'.
• · The Spin-Out transferred legacy biopharmaceutical operations to Coeptis Holdings, Inc. (CHI), which are no longer part of the consolidated business.
• · GEAR Therapeutics was retained, and CHI received an option to acquire GEAR at fair market value, exercisable from October 24, 2026 for 24 months.

09-06-2026

Onconetix, Inc. filed an S-1 registration statement for a proposed securities offering. The company is a commercial-stage biotechnology firm focused on oncology, owning Proclarix, an in vitro diagnostic test for prostate cancer approved in the EU and being developed in the U.S. via a LabCorp agreement. However, the company has incurred net losses since inception, abandoned commercialization of its only other product (ENTADFI), and faces substantial doubt about its ability to continue as a going concern, with cash of only $3.7 million as of March 31, 2026, and an accumulated deficit of $135.4 million.

• · Proclarix is CE-marked and for sale in Europe; in the UK, ~100 tests were carried out in a screening initiative as of March 31, 2026.
• · Two peer-reviewed publications on Proclarix were published in Q1 2026: one in BMC Cancer (Schiess et al., 371 men) and one in Cancers (Athanasiou et al., 132 men).
• · Proteomedix initiated a multi-center PRIME study with LabCorp to evaluate Proclarix in the U.S., targeting up to 500 men; first participants enrolled.
• · The company abandoned commercialization of ENTADFI as of December 31, 2025, and terminated three employees involved with the program.
• · Onconetix has no internal manufacturing capabilities and relies on single-source third-party suppliers for Proclarix.
• · The company believes its current cash balance is not sufficient to fund operations for one year from the date of issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern.

09-06-2026

Wolfspeed, Inc. filed an S-1 registration statement on June 9, 2026, registering up to 24,072,041 shares of common stock for resale by selling stockholders, including major holders like Renesas Electronics America Inc. (39.9% beneficial owner) and entities managed by Whitebox Advisors LLC (9.9%). The company emerged from Chapter 11 bankruptcy on September 29, 2025, and converted to a Delaware corporation; it will not receive any proceeds from the resale, though it will receive the nominal exercise price of Pre-Funded Warrants. As of May 31, 2026, Wolfspeed had 51,972,101 shares outstanding, with the stock trading at $55.42 per share on June 8, 2026.

• · Wolfspeed emerged from Chapter 11 bankruptcy on September 29, 2025, and converted to a Delaware corporation.
• · The company has never declared or paid any cash dividends and does not anticipate doing so in the foreseeable future.
• · The offering is solely for the selling stockholders' account; Wolfspeed will not receive any proceeds except the nominal exercise price of Pre-Funded Warrants.
• · The selling stockholders will pay underwriting fees and commissions; Wolfspeed will bear all other registration costs.
• · The stock is listed on the NYSE under the symbol 'WOLF' and closed at $55.42 on June 8, 2026.
• · Renesas Electronics America Inc. is the largest beneficial owner at 39.9%, with 23,315,760 shares (including shares issuable upon conversion of Renesas 2L Convertible Notes).
• · No named executive officer or director beneficially owns more than 1% of outstanding shares.

09-06-2026

Starfighters Space, Inc. filed an S-1 registration statement for an initial public offering. The company reported a net loss of $3.5 million for the three months ended March 31, 2026, compared to a net loss of $2.1 million for the same period in 2025, representing a 67% increase in losses. However, total assets grew to $4.2 million as of March 31, 2026, from $3.1 million at December 31, 2025, a 35% increase.

• · The company has incurred significant losses and expects to continue incurring losses for the foreseeable future.
• · The filing includes convertible debt tranches with varying terms and fair value inputs.
• · Subsequent events include grants of restricted stock units and stock options to directors, officers, and family members of former CEO.

09-06-2026

SOBR Safe, Inc. filed an S-4 registration statement on June 9, 2026, in connection with a business combination. The filing includes extensive financial data and disclosures about the company's capital structure, insider trading policy, and various equity and debt instruments. The company has a going concern qualification and significant accumulated deficits, indicating ongoing financial challenges.

• · The company's accumulated deficit was $15,631,829.60 as of March 31, 2026.
• · Common stock outstanding decreased from 3,366 shares at December 31, 2025 to 748 shares at March 31, 2026.
• · The company has a going concern qualification in its financial statements.
• · The Insider Trading Policy was adopted by the Board of Directors on May 31, 2024.
• · The filing includes details on Series A and Series B warrants, convertible notes, and various equity incentive plans.

09-06-2026

Broadcom Inc. filed an S-4 registration statement on June 9, 2026, to register an exchange offer for up to $3,249,984,000 of 3.137% Senior Notes due 2035 and up to $2,750,000,000 of 3.187% Senior Notes due 2036, originally issued in a private exchange on September 30, 2021. The exchange offer is being made to fulfill registration rights and will not generate any cash proceeds for Broadcom. The exchange is not conditioned on a minimum tender amount, and the company does not currently intend to extend the expiration date.

• · The exchange offer expires at 5:00 p.m., New York City time, on a date to be filled in (five business days before expiration), unless extended.
• · Outstanding Notes may be exchanged only in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.
• · Interest on the Exchange Notes accrues from May 15, 2026.
• · The exchange is not conditioned upon any minimum aggregate principal amount being tendered.
• · Holders who do not tender their Outstanding Notes will continue to be subject to transfer restrictions and will lose further registration rights.
• · The exchange of Outstanding Notes for Exchange Notes will not constitute a taxable event for U.S. federal income tax purposes.
• · Broadcom will not receive any cash proceeds from the issuance of Exchange Notes.